Kubota Pharmaceutical Holdings Company Description

Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide.

Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy.

The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control.

The company was founded in 2002 and is based in Tokyo, Japan.

Kubota Pharmaceutical Holdings Co., Ltd.

Country	Japan
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	19
CEO	Ryo Kubota

Contact Details

Address: 3-7-1 Kasumigaseki Tokyo Japan
Phone	81 3 6550 8928
Website	kubotaholdings.co.jp

Stock Details

Ticker Symbol	4596
Exchange	Tokyo Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	JPY
ISIN Number	JP3266500002
SIC Code	2834

Key Executives

Name	Position
Ryo Kubota	Chief Executive Officer
Tomomi Sukagawa	Head of Investor Relations